The Food and Drug Administration’s latest tactic for driving down prescription drug costs: publicly naming and shaming prescription drug makers that try to block generic equivalents of their products.
FDA Commissioner Scott Gottlieb announced the FDA’s new strategy to encourage generic drugs on Thursday, describing efforts to shine light “on situations where drug makers may be pursuing gaming tactics to delay generic competition.”
